Monday, November 9, 2020
- 9:00AM-11:00AM
-
Abstract Number: 1920
Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis and Visual Impairment
Vasculitis – Non-ANCA-Associated & Related Disorders Poster II- 9:00AM-11:00AM
-
Abstract Number: 1926
Efficacy of Adjunctive Methotrexate in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Subanalysis of a Phase 3 Trial
Vasculitis – Non-ANCA-Associated & Related Disorders Poster II- 9:00AM-11:00AM
-
Abstract Number: 1749
Efficacy of Filgotinib in Patients with Rheumatoid Arthritis with Poor Prognostic Factors: Post Hoc Analysis
RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease- 9:00AM-11:00AM
-
Abstract Number: 1598
Efficacy of Universal Depression Screening in a Rheumatology Clinic
Measures & Measurement of Healthcare Quality Poster- 9:00AM-11:00AM
-
Abstract Number: 1855
Elevated Calprotectin Levels Reveal Loss of Vascular Pattern and Atrophy of Villi in Ileum Using Digital Chromo-endoscopy and Magnification Colonoscopy in Patients with Spondyloarthritis Without Inflammatory Bowel Disease
Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster- 9:00AM-11:00AM
-
Abstract Number: 1666
Elucidating Research Priorities in Childhood-Onset Systemic Lupus Erythematosus: A Qualitative Study
Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM- 9:00AM-11:00AM
-
Abstract Number: 1808
Erythrocyte Complement Receptor 1 (ECR1) and Erythrocyte Bound C4d (EC4d) Associate with Adverse Pregnancy Outcomes and Preeclampsia in Pregnant Women with Systemic Lupus Erythematosus (SLE)
SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside- 9:00AM-11:00AM
-
Abstract Number: 1908
Establishment of iPSc and Differentiated Endothelial Cells of Systemic Sclerosis Associated Pulmonary Arterial Hypertension ; Functional and Molecular Analysis
Systemic Sclerosis & Related Disorders – Basic Science Poster- 9:00AM-11:00AM
-
Abstract Number: 1634
Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments?
Miscellaneous Rheumatic & Inflammatory Diseases Poster III: Therapies- 9:00AM-11:00AM
-
Abstract Number: 1643
Evaluating Analgesic Response to Subcutaneous Tanezumab in Patients with Inadequate Treatment Response to Other Analgesics Based on Daily E-pain Diaries: A Pooled Analysis of 2 Randomized, Placebo-controlled Studies
Osteoarthritis – Clinical Poster II- 9:00AM-11:00AM
-
Abstract Number: 1846
Evaluating the Risk of QT-prolongation Associated with Hydroxychloroquine Use with and Without Antidepressants in SLE Patients with Fibromyalgia
SLE – Treatment Poster II- 9:00AM-11:00AM
-
Abstract Number: 1693
Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease
Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM- 9:00AM-11:00AM
-
Abstract Number: 1835
Evaluation of Low Dose Glucocorticoid Effects on Infection Occurrence in Systemic Lupus Erythematosus Patients
SLE – Treatment Poster II- 9:00AM-11:00AM
-
Abstract Number: 1883
Exercise Partially Explains the Impact of Body Mass Index on Disease Activity in Ankylosing Spondylitis